Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
1 finding from 1 review
Death (any cause) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
1 finding from 1 review
Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
1 finding from 1 review
Minor bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).
1 finding from 1 review
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review
Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 6 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy
1 finding from 1 review